Literature DB >> 25083189

Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazoles.

Nihar Ranjan1, Geraldine Fulcrand2, Ada King3, Joseph Brown4, Xiuping Jiang4, Fenfei Leng2, Dev P Arya5.   

Abstract

Hoechst dyes are well known DNA binders that non-selectively inhibit the function of mammalian topoisomerase I and II. Herein, we show that Hoechst 33258 based bisbenzimidazoles (DPA 151-154), containing a terminal alkyne, are effective and selective inhibitors of E. coli. topoisomerase I. These bisbenzimidazoles displayed topoisomerase I inhibition much better than Hoechst 33342 or Hoechst 33258 with IC50 values in the range of 2.47-6.63 μM. Bisbenzimidazoles DPA 151-154 also display selective inhibition of E. coli. topoisomerase I over DNA gyrase and Human topoisomerases I and II, and effectively inhibit bacterial growth.

Entities:  

Year:  2014        PMID: 25083189      PMCID: PMC4112416          DOI: 10.1039/C4MD00140K

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  23 in total

Review 1.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

Review 2.  Topoisomerase I poisons and suppressors as anticancer drugs.

Authors:  C Bailly
Journal:  Curr Med Chem       Date:  2000-01       Impact factor: 4.530

3.  Recognition of B-DNA by neomycin--Hoechst 33258 conjugates.

Authors:  Bert Willis; Dev P Arya
Journal:  Biochemistry       Date:  2006-08-29       Impact factor: 3.162

4.  Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.

Authors:  Laixing Hu; Maureen L Kully; David W Boykin; Norman Abood
Journal:  Bioorg Med Chem Lett       Date:  2009-05-20       Impact factor: 2.823

5.  DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.

Authors:  A Y Chen; C Yu; B Gatto; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

6.  DNA sequence recognition by Hoechst 33258 conjugates of hairpin pyrrole/imidazole polyamides.

Authors:  Bryan J Correa; Daniele Canzio; Alexandra L Kahane; Putta Mallikarjuna Reddy; Thomas C Bruice
Journal:  Bioorg Med Chem Lett       Date:  2006-05-08       Impact factor: 2.823

7.  Design of new bidentate ligands constructed of two Hoechst 33258 units for discrimination of the length of two A3T3 binding motifs.

Authors:  Mikimasa Tanada; Saori Tsujita; Shigeki Sasaki
Journal:  J Org Chem       Date:  2006-01-06       Impact factor: 4.354

8.  Synthesis and antimycobacterial activity of 2-substituted halogenobenzimidazoles.

Authors:  Z Kazimierczuk; M Andrzejewska; J Kaustova; V Klimesova
Journal:  Eur J Med Chem       Date:  2005-02       Impact factor: 6.514

9.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

10.  SAR study of clubbed [1,2,4]-triazolyl with fluorobenzimidazoles as antimicrobial and antituberculosis agents.

Authors:  Ganesh Rajaram Jadhav; Mohammad Usman Shaikh; Rajesh Prabhakar Kale; Mahendra Ramesh Shiradkar; Charansingh Harnamsingh Gill
Journal:  Eur J Med Chem       Date:  2008-12-16       Impact factor: 6.514

View more
  7 in total

Review 1.  Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.

Authors:  Yuk-Ching Tse-Dinh
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

2.  New Application of Neomycin B-Bisbenzimidazole Hybrids as Antifungal Agents.

Authors:  Nishad Thamban Chandrika; Sanjib K Shrestha; Nihar Ranjan; Anindra Sharma; Dev P Arya; Sylvie Garneau-Tsodikova
Journal:  ACS Infect Dis       Date:  2017-12-11       Impact factor: 5.084

3.  Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.

Authors:  Nishad Thamban Chandrika; Sanjib K Shrestha; Huy X Ngo; Sylvie Garneau-Tsodikova
Journal:  Bioorg Med Chem       Date:  2016-06-04       Impact factor: 3.641

4.  Perspectives on the Clinical Development of NRF2-Targeting Drugs.

Authors:  Diego Lastra; Raquel Fernández-Ginés; Gina Manda; Antonio Cuadrado
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Gram-negative synergy and mechanism of action of alkynyl bisbenzimidazoles.

Authors:  Jordan Chamberlin; Sandra Story; Nihar Ranjan; Geoffrey Chesser; Dev P Arya
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

Review 6.  Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development.

Authors:  Natalia Robledinos-Antón; Raquel Fernández-Ginés; Gina Manda; Antonio Cuadrado
Journal:  Oxid Med Cell Longev       Date:  2019-07-14       Impact factor: 6.543

Review 7.  Type IA Topoisomerases as Targets for Infectious Disease Treatments.

Authors:  Ahmed Seddek; Thirunavukkarasu Annamalai; Yuk-Ching Tse-Dinh
Journal:  Microorganisms       Date:  2021-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.